A Low-Cost Instrumented Shoe System for Gait Phase Detection Based on Foot Plantar Pressure Data.

This paper presents a novel low-cost and fully-portable instrumented shoe system for gait phase detection. The instrumented shoe consists of 174 independent sensing units constructed based on an off-the-shelf force-sensitive film known as the Velostat conductive copolymer. A zero potential method was implemented to address the crosstalk effect among the matrix-formed sensing arrays. A customized algorithm for gait event and phase detection was developed to estimate stance sub-phases including initial contact, flat foot, and push off. Experiments were carried out to evaluate the performance of the proposed instrumented shoe system in gait phase detection for both straight-line walking and turning walking. The results showed that the mean absolute time differences between the estimated phases by the proposed instrumented shoe system and the reference measurement ranged from 45 to 58 ms during straight-line walking and from 51 to 77 ms during turning walking, which were comparable to the state of art.Clinical and Translational Impact Statement-By allowing convenient gait monitoring in home healthcare settings, the proposed system enables extensive ADL data collection and facilitates developing effective treatment and rehabilitation strategies for patients with movement disorders.

Characteristics of foot plantar pressure during turning in young male adults.

BACKGROUND: Turning gait is considered as a challenging motor task. However, only few existing studies reported turning biomechanics from the aspect of foot plantar pressure. RESEARCH QUESTION: This study aimed to investigate turning biomechanics by studying foot plantar pressure characteristics METHODS: Twelve young male participants were involved in this experimental study. They were instructed to perform turning tasks with different turning angles (i.e., 30°, 60°, and 90°). Foot plantar pressure was quantified by the force time integral (FTI) underneath seven plantar sub-areas. Analysis was carried out for different turning strategies (spin turns versus step turns), separately. RESULTS: The results showed that for small-angle spin turns, plantar pressure patterns changed at the early stage of the approaching step, suggesting a preparatory action for the increased lower limb range of motion in the transverse plane during turning; for step turns, an imbalance weight bearing mechanism was adopted when making large-angle turns to compensate for the centripetal force during turning. SIGNIFICANCE: The findings provide improved knowledge about turning biomechanics. They have practical implications for motion planning of lower-limb assistive devices for those with difficulties in turning.

Itaconate alleviates ß2-microglobulin-induced cognitive impairment by enhancing the hippocampal amino-ß-carboxymuconate-semialdehyde-decarboxylase/picolinic acid pathway.

ß2-microglobulin (B2M) has been established to impair cognitive function. However, no treatment is currently available for B2M-induced cognitive dysfunction. Itaconate is a tricarboxylic acid (TCA) cycle intermediate that exerts neuroprotective effects in several neurological diseases. The amino-ß-carboxymuconate-semialdehyde-decarboxylase (ACMSD)/picolinic acid (PIC) pathway is a crucial neuroprotective branch in the kynurenine pathway (KP). The present study sought to investigate whether Itaconate attenuates B2M-induced cognitive impairment and examine the mediatory role of the hippocampal ACMSD/PIC pathway. We demonstrated that 4-Octyl Itaconate (OI, an itaconate derivative) significantly alleviated B2M-induced cognitive dysfunction and hippocampal neurogenesis impairment. OI treatment also increased the expression of ACMSD, elevated the concentration of PIC, and decreased the level of 3-HAA in the hippocampus of B2M-exposed rats. Furthermore, inhibition of ACMSD by TES-991 significantly abolished the protections of Itaconate against B2M-induced cognitive impairment and neurogenesis deficits. Exogenous PIC supplementation in hippocampus also improved cognitive performance and hippocampal neurogenesis in B2M-exposed rats. These findings demonstrated that Itaconate alleviates B2M-induced cognitive impairment by upregulation of the hippocampal ACMSD/PIC pathway. This is the first study to document Itaconate as a promising therapeutic agent to ameliorate cognitive impairment. Moreover, the mechanistic insights into the ACMSD/PIC pathway improve our understanding of it as a potential therapeutic target for neurological diseases beyond B2M-associated neurocognitive disorders.